<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<pubmed-document>
<record>
<header>
<identifier>19623420</identifier>
<setSpec>0034-9887</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:author>de la Fuente, Hernán</dc:author>
<dc:author>Gil, M Cecilia</dc:author>
<dc:author>Butte, Jean M</dc:author>
<dc:author>Amaral, Horacio</dc:author>
<dc:author>Pruzzo, Rossana</dc:author>
<dc:author>Pizarro, Alejandra</dc:author>
<dc:author>Coudeu, T M Irene</dc:author>
<dc:author>Redondo, Francisca</dc:author>
<dc:description xml:lang="en">We report a 74-year-old male with liver metastases from a neuroendocrine tumor (NET) of unknown origin. Conventional imaging studies with ultrasound, computed tomography colonoscopy and Positron emission tomography-computed tomography (PET/CT) with 18Fluor odeoxyglucose did not identify the site of origin of the primary tumor. The patient was submitted for a PET/CT scan with a new radiopharmaceuticai, the somatostatin analogue 68Ga-DOTATATE. This new technique demonstrated increased focal uptake at the ileocecal valve. This lesion and other two liver metastases were surgically removed. The histopathology and immunohistochemistry analysis confirmed the diagnosis of NET (carcinoid). This case illustrates the advantages of the PET/CT scan with 68Ga-DOTATATE.</dc:description>
<dc:type>Case Reports</dc:type>
<dc:language>es</dc:language>
<dc:date>2009 Apr </dc:date>
<dc:title xml:lang="es">Una nueva modalidad diagnóstica para la detección de tumores neuroendocrinos con 68Ga-DOTATATE PET/CT: caso clínico.</dc:title>
<dc:title xml:lang="en">[Detection of neuroendocrine tumors by positron emission tomography-computed tomography with 68Ga-DOTATATE: report of one case].</dc:title>
<dc:publisher>Revista medica de Chile</dc:publisher>
</metadata>
</record>
</pubmed-document>
